Friess Associates’s Repligen RGEN Stock Holding History

Friess Associates’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-611	Closed	-$119K	–	106
2021 Q1	$119K	Sell	611 -128,819	-100%	-$26.4M	0.05%	77
2020 Q4	$24.8M	Buy	129,430 +8,524	+7%	+$1.55M	1.83%	18
2020 Q3	$17.8M	Buy	+120,906	New	+$17.3M	1.55%	33
2017 Q3	–	Sell	-155,000	Closed	-$6.42M	–	117
2017 Q2	$6.42M	Buy	+155,000	New	+$5.89M	0.58%	72
2017 Q1	–	Sell	-21,730	Closed	-$670K	–	152
2016 Q4	$670K	Sell	21,730 -820	-4%	-$25.4K	0.07%	101
2016 Q3	$681K	Buy	22,550 +1,450	+7%	+$43.8K	0.07%	101
2016 Q2	$577K	Hold	21,100	–	–	0.06%	100
2016 Q1	$566K	Hold	21,100	–	–	0.06%	103
2015 Q4	$597K	Buy	+21,100	New	+$608K	0.06%	98
2014 Q4	–	Sell	-14,000	Closed	-$279K	–	160
2014 Q3	$279K	Buy	+14,000	New	+$295K	0.02%	97
2014 Q2	–	Sell	-354,500	Closed	-$4.56M	–	164
2014 Q1	$4.56M	Buy	+354,500	New	+$5.08M	0.36%	69
2013 Q3	–	Sell	-75,000	Closed	-$618K	–	165
2013 Q2	$618K	Buy	+75,000	New	+$630K	0.05%	78

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Friess Associates's RGEN Position: Q2 2021 in Review

Friess Associates sold out of Repligen (RGEN) in Q2 2021, closing a stake of 611 shares — an estimated $119K sold.

Friess Associates first reported a position in RGEN in Q2 2013 and held it in 12 quarters. The position peaked at $24.8M in Q4 2020. 428 funds tracked by Wall St. Rank hold RGEN as of Q2 2021.

Friess Associates reported no remaining Repligen position as of Q2 2021 after selling out during the quarter.
Friess Associates sold 611 Repligen shares in Q2 2021, an estimated $119K.
Friess Associates first reported a position in Repligen in Q2 2013 and held it in 12 quarters.
Friess Associates's Repligen position peaked at $24.8M in Q4 2020.
428 funds tracked by Wall St. Rank held Repligen as of Q2 2021.

Based on Friess Associates's 13F filing for Q2 2021, filed 11 Aug 2021.